Ignite Creation Date:
2024-05-05 @ 5:08 PM
Last Modification Date:
2024-10-26 @ 9:28 AM
Study NCT ID:
NCT00391144
Status:
UNKNOWN
Last Update Posted:
2006-10-23
First Post:
2006-10-20
Brief Title:
Avastin for CNV Secondary to Pattern Dystrophy
Sponsor:
University of Trieste
Organization:
University of Trieste
Study Overview
Official Title:
Intravitreal Avastin Injection for the Treatment of Choroidal Neovascularization Secondary to Pattern Dystrophy
Status:
UNKNOWN
Status Verified Date:
2006-10
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The natural history of subfoveal CNV secondary to Pattern Dystrophy is little understood but it seems that visual function may be preserved only in the short-term follow-up with progressive deterioration thereafter
Photodynamic therapy with verteporfin is the most studied therapeuthic option for this kindf of lesion but unfortunately this approach does not appear to guarantee long-term vision stabilization and alternative therapies should be investigated
Photodynamic therapy with verteporfin is the most studied therapeuthic option for this kindf of lesion but unfortunately this approach does not appear to guarantee long-term vision stabilization and alternative therapies should be investigated
Detailed Description:
Diagnosis of Pattern Dystrophy Diagnosis of subfoveal CNV Intravitreal injection of avastin 125 mg in operating room under sterile condition
Retreatment on the basis of the detection of disease progression and of lack of central retinal thickness reduction on OCT
Retreatment on the basis of the detection of disease progression and of lack of central retinal thickness reduction on OCT
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None